Personally, I am speculating that a major amount of the risk in this investment will disappear during the course of the six “Upcoming Events” listed on PPHM website, starting Oct 5 and running through Nov 7:
During that same time period, I expect three major endorsements of PPHM will occur:
First, the R&R kick-off report explaining each drug in Peregrine’s very large pipeline and putting a dollar value on it.
Second, a Duke / Chavi publication that includes results from the SIV monkey trial.
Third, an announcement that the DTRA $44 million contract has closed
These three endorsements will give the Company independent, third-party credibility and set the stage for serious institutional buying. Of course the clinical data from HIV/HCV and Ph II cancer and Cotara trials that arrives Nov.-April will be the biggest value driver, but you can start sleeping soundly as soon as the R&R report is published. Every sentence in that report will be supported by the hard due diligence that’s happening right now.
News 
Market Data 
Discover 
AI
